04.18.24 -- Process Development: Stuck In The Middle With You

From raw materials to finished dosage forms, understanding material quality is essential in drug manufacturing. This article examines how material grades and sources guide selection for optimal safety and functionality.

Increased demand for protein delivery and the emergence of advanced modalities – including mRNA – are introducing new challenges to the development lifecycle, such as high-concentration formulations.

While breakthroughs with mRNA vaccines have ignited renewed interest in nucleic acid medicines, the road to wide adoption will present many challenges. Learn more about the future of these therapeutics.

A CDMO’s ability to scale seamlessly between bioreactor sizes is critical when adopting a client’s manufacturing process.

Hear from experienced professionals in drug delivery on how to ensure success and speed-to-market by establishing a firm foundation when working with a CMO.

Rapid development of high-quality cell lines is vital to biomanufacturing projects. How developers approach the fundamental steps can define their core biologics capabilities and keep projects on track.

An emerging biotech company sought help developing a formulation for a monoclonal antibody. Review the solution that delivered an optimized formulation within an aggressive timeline and budget.

Despite the growing body of research and scientific knowledge, perhaps the biggest challenge with LNP formulation is the journey into the unknown.

Join us on May 1st to learn the latest in nanotechnology. Recent developments in leading nanotechnologies are enabling new formulation possibilities for more products, providing a better patient experience and stronger differentiation for biopharma innovators. Discover new data on nanotechnology and how to tackle drug loading and pill burden issues associated with amorphous solid dispersion formulations. Click here to learn more.

Discover how key partnerships can help provide clients insight into potential product degradation inflicted during the final product distribution process and provide transport validation support.

At Abzena, the leading CDMO + CRO for complex biologics and bioconjugates, our focus is on providing a de-risked and streamlined development pathway for our customers.

Learn how a CDMO can offer biopharma companies the flexible capacity they need to meet the growing needs for medicines today and in the future.